Ambarish Pandey, MD

Articles by Ambarish Pandey, MD

Don't Miss a Beat: POLY-HF & the Potential of Polypills in HF, With Ambarish Pandey, MD

ByMuthiah Vaduganathan, MD, MPH,Stephen J. Greene, MD, FACC, FHFSA,Ambarish Pandey, MD

November 13th 2025

Cohosts Stephen Greene, MD, and Muthiah Vaduganathan, MD, sat down with Ambarish Pandey, MD, to discuss the revolutionary POLY-HF trial and how polypills can fit into heart failure treatment.

Four panelist discusses how advancing diagnostic precision, integrating novel MRAs like finerenone, and addressing real-world barriers in access and adherence are transforming HFpEF care and improving patient outcomes.

Navigating Access Barriers and Treatment Gaps in HFpEF Care

ByJaved Butler, MD, MPH, MBA,Josephine Harrington, MD,Stephen J. Greene, MD, FACC, FHFSA,Ambarish Pandey, MD

October 8th 2025

The discussion concludes with strategies to overcome access barriers and ensure equitable implementation of novel HFpEF therapies.

Challenges With Combining Nonsteroidal MRAs and Treatment Adherence in HFpEF

ByJaved Butler, MD, MPH, MBA,Josephine Harrington, MD,Stephen J. Greene, MD, FACC, FHFSA,Ambarish Pandey, MD

October 8th 2025

Panelists address adherence challenges and the need for careful coordination when integrating nonsteroidal MRAs into multifaceted treatment plans.

Strategies for Prevention of HFpEF

ByJaved Butler, MD, MPH, MBA,Josephine Harrington, MD,Stephen J. Greene, MD, FACC, FHFSA,Ambarish Pandey, MD

October 8th 2025

Experts highlight preventive approaches, including risk factor control and early therapeutic intervention, to mitigate HFpEF development.

MRA Combination Therapies and Monitoring in HFpEF

ByJaved Butler, MD, MPH, MBA,Josephine Harrington, MD,Stephen J. Greene, MD, FACC, FHFSA,Ambarish Pandey, MD

October 8th 2025

Discussion centers on combining MRAs with other agents while maintaining vigilant monitoring to minimize risks and optimize long-term management.

Sequencing Therapies in HFpEF Care

ByJaved Butler, MD, MPH, MBA,Josephine Harrington, MD,Stephen J. Greene, MD, FACC, FHFSA,Ambarish Pandey, MD

October 8th 2025

Panelists share insights on how best to sequence MRAs, SGLT2 inhibitors, and ARNis to maximize patient outcomes and adherence.

Selecting MRAs in HFpEF in Patients With Comorbidities

ByJaved Butler, MD, MPH, MBA,Josephine Harrington, MD,Stephen J. Greene, MD, FACC, FHFSA,Ambarish Pandey, MD

October 8th 2025

The panel focuses on balancing efficacy and safety when choosing MRAs for patients with HFpEF with complex comorbid conditions such as CKD and diabetes.

Finerenone Benefits and Anticipated Guideline Updates for HFpEF

ByJaved Butler, MD, MPH, MBA,Josephine Harrington, MD,Stephen J. Greene, MD, FACC, FHFSA,Ambarish Pandey, MD

October 8th 2025

Experts discuss the clinical implications of finerenone’s benefits and forecast how upcoming guidelines may shift standard care practices.

FINEARTS-HF Trial and Finerenone Approval in HFpEF

ByJaved Butler, MD, MPH, MBA,Josephine Harrington, MD,Stephen J. Greene, MD, FACC, FHFSA,Ambarish Pandey, MD

October 8th 2025

The group reviews key findings from FINEARTS-HF and discusses how finerenone’s approval expands treatment options for patients with HFpEF.

Aldosterone Antagonist for Treatment of HFpEF

ByJaved Butler, MD, MPH, MBA,Josephine Harrington, MD,Stephen J. Greene, MD, FACC, FHFSA,Ambarish Pandey, MD

October 8th 2025

Panelists explore the mechanistic benefits of aldosterone antagonism and its evolving role within HFpEF therapeutic frameworks.

Nonsteroidal vs Steroidal MRAs in HFpEF

ByJaved Butler, MD, MPH, MBA,Josephine Harrington, MD,Stephen J. Greene, MD, FACC, FHFSA,Ambarish Pandey, MD

October 8th 2025

The conversation compares the efficacy and safety of nonsteroidal and steroidal MRAs, focusing on clinical decision-making and patient selection.

Evolving Guideline-Directed Medical Therapy Standards in HFpEF

ByJaved Butler, MD, MPH, MBA,Josephine Harrington, MD,Stephen J. Greene, MD, FACC, FHFSA,Ambarish Pandey, MD

October 8th 2025

Experts examine how updated guidelines are influencing the integration of novel MRAs and other agents into HFpEF treatment algorithms.

Quality of Life and Hospitalization Burden in HFpEF

ByJaved Butler, MD, MPH, MBA,Josephine Harrington, MD,Stephen J. Greene, MD, FACC, FHFSA,Ambarish Pandey, MD

October 8th 2025

Panelists emphasize strategies to enhance patient quality of life and reduce hospital readmissions through optimized therapeutic management.

Early Identification Strategies in HFpEF

ByJaved Butler, MD, MPH, MBA,Josephine Harrington, MD,Stephen J. Greene, MD, FACC, FHFSA,Ambarish Pandey, MD

October 8th 2025

The discussion centers on proactive screening and early intervention approaches to improve outcomes and slow HFpEF progression.

Diagnostic Workup for Suspected HFpEF

ByJaved Butler, MD, MPH, MBA,Josephine Harrington, MD,Stephen J. Greene, MD, FACC, FHFSA,Ambarish Pandey, MD

October 8th 2025

Experts highlight the importance of precise diagnostic criteria and multimodal assessments to distinguish HFpEF from overlapping cardiovascular conditions.

Epidemiology and Classification of Heart Failure Based on Ejection Fraction

ByJaved Butler, MD, MPH, MBA,Josephine Harrington, MD,Stephen J. Greene, MD, FACC, FHFSA,Ambarish Pandey, MD

October 8th 2025

Panelists discuss how evolving diagnostic precision, evidence-based MRA use, and combination therapy strategies are transforming HFpEF care while addressing real-world challenges in access and adherence.